- Repligen projects organic revenue growth for 2025 to be between 9.5% and 13.5%.
- The estimated figure for organic revenue growth stands at 9.15%.
- Projected adjusted earnings per share (EPS) are between $1.67 and $1.76, with an estimate of $1.66.
- Repligen anticipates total revenue between $685 million and $710 million for 2025.
- The company expects an adjusted gross margin of 51% to 52%, while the estimate is 51.3%.
- In the fourth quarter, adjusted EPS was reported at 44 cents, compared to 33 cents year-over-year, surpassing the estimate of 41 cents.
- Fourth-quarter revenue reached $167.5 million, marking a 7.6% increase year-over-year.
- Adjusted EBITDA for the fourth quarter was $35.1 million, a 34% increase year-over-year, exceeding the estimate of $33.6 million.
- Orders exceeded revenue by 6% in the fourth quarter.
- Full-year 2025 revenue guidance indicates 8% to 12% reported growth, and 10% to 14% excluding COVID-related revenue.
- Market sentiment includes 15 buy ratings, 5 hold ratings, and no sell ratings.
A look at Repligen Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Repligen Corporation, a bioprocessing company specializing in innovative products for biologic drug manufacturing, has a mixed outlook based on the Smartkarma Smart Scores. While scoring moderately in Value, Growth, and Momentum, the company falls short in Dividend payout. Repligen’s resilience factor, however, remains strong, showcasing its ability to withstand market challenges and maintain stability.
Despite facing challenges in the dividend category, Repligen Corp‘s overall outlook appears positive in the long term. With a focus on developing and commercializing cutting-edge bioprocessing products for a global customer base, the company’s resilience and growth potential provide a solid foundation for future success in the biopharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
